{"nctId":"NCT02580591","briefTitle":"Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)","startDateStruct":{"date":"2015-12-22","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 1"],"count":977,"armGroups":[{"label":"Empagliflozin low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin","Drug: Placebo"]},{"label":"Empagliflozin high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin","Drug: Placebo"]},{"label":"Empagliflozin medium dose","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Empagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Signed and dated written informed consent\n* Male or female patient receiving insulin for the treatment of documented diagnosis of type 1 diabetes mellitus (T1DM) \\> 1 year\n* C-peptide value of \\< 0.7 ng/mL\n* Use of Multiple Daily Injections (MDI) of insulin or insulin pump user with total daily insulin \\>= 0.3 and \\<= 1.5 U/kg\n* Glycated haemoglobin (HbA1c) \\>= 7.5% and \\<= 10.0%\n* Good understanding of T1DM\n* Age \\>= 18 years\n* Body Mass Index (BMI) \\>= 18.5 kg/m2\n* Estimated glomerular filtration rate \\>= 30 mL/min/1.73 m2\n* Women of child-bearing potential must use highly effective methods of birth control\n* Compliance with trial medication administration between 80% and 120% during placebo run-in period Further inclusion criteria apply\n\nExclusion criteria:\n\n* History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis\n* Pancreas, pancreatic islet cells or renal transplant recipient\n* T1DM treatment with any other antihyperglycaemic drug except subcutaneous basal and bolus insulin within last 3 months\n* Occurrence of severe hypoglycaemia within last 3 months and until randomisation\n* Occurence of diabetic ketoacidosis within 3 months prior to Visit 1 and until Visit 6\n* Irregular sleep/wake cycle\n* Acute coronary syndrome, stroke or Transient Ischaemic Attack (TIA) within last 3 months\n* Severe gastroparesis\n* Brittle diabetes\n* Liver disease\n* Eating disorders\n* Treatment with anti-obesity drugs, weight-loss surgery or aggressive diet regimen\n* Treatment with systemic corticosteroids\n* Change in dose of thyroid hormones within last 6 weeks and until randomisation\n* Cancer or treatment for cancer in the last five years\n* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells\n* Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial\n* Alcohol or drug abuse\n* Intake of an investigational drug in another trial within last 30 days Further exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])","description":"Change from baseline in Glycated hemoglobin (HbA1c) for full analysis set (FAS) (observed cases \\[OC\\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.05"},{"groupId":"OG001","value":"-0.09","spread":"0.05"},{"groupId":"OG002","value":"-0.25","spread":"0.05"},{"groupId":"OG003","value":"-0.33","spread":"0.05"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))","description":"Change from baseline in Glycated hemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \\[OC-AD\\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.05"},{"groupId":"OG001","value":"-0.06","spread":"0.05"},{"groupId":"OG002","value":"-0.23","spread":"0.05"},{"groupId":"OG003","value":"-0.30","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)","description":"Rate per patient-year of investigator-reported symptomatic hypoglycemic adverse events (AEs) with confirmed plasma glucose (PG) \\<54 milligram per deciliter (mg/dL) (\\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycemic AEs (i.e. all investigator-reported AEs that had confirmed PG \\<54 mg/dL \\[\\<3.0 mmol/L\\] with symptoms reported and all severe hypoglycemic events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate. This is key secondary endpoints.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.13","spread":null},{"groupId":"OG001","value":"5.77","spread":null},{"groupId":"OG002","value":"7.37","spread":null},{"groupId":"OG003","value":"6.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.62","spread":null},{"groupId":"OG001","value":"6.17","spread":null},{"groupId":"OG002","value":"8.33","spread":null},{"groupId":"OG003","value":"6.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 26","description":"Change from baseline in body weight is presented With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.20"},{"groupId":"OG001","value":"-1.55","spread":"0.20"},{"groupId":"OG002","value":"-2.83","spread":"0.20"},{"groupId":"OG003","value":"-3.22","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26","description":"Change from baseline in Total daily insulin dose (TDID) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.011","spread":"0.007"},{"groupId":"OG001","value":"-0.060","spread":"0.007"},{"groupId":"OG002","value":"-0.080","spread":"0.007"},{"groupId":"OG003","value":"-0.102","spread":"0.007"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26","description":"Change from baseline in Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.7"},{"groupId":"OG001","value":"-1.7","spread":"0.7"},{"groupId":"OG002","value":"-3.5","spread":"0.7"},{"groupId":"OG003","value":"-3.4","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.4"},{"groupId":"OG001","value":"-0.4","spread":"0.4"},{"groupId":"OG002","value":"-1.8","spread":"0.4"},{"groupId":"OG003","value":"-1.5","spread":"0.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":241},"commonTop":["Hypoglycaemia","Nasopharyngitis","Urinary tract infection","Blood ketone body increased"]}}}